Funxional Announces Successful Completion of the Phase I Programme of Its Novel Anti-Inflammatory Small Molecule, FX125L

Bookmark and Share

CAMBRIDGE, England--(BUSINESS WIRE)--Funxional Therapeutics Ltd (Funxional) has announced today the successful completion of the Phase I programme of its novel anti-inflammatory, FX125L, an orally available small molecule that belongs to a new therapeutic class named Broad Spectrum Chemokine Inhibitors (BSCIs).
MORE ON THIS TOPIC